German medical software company CompuGroup Medical has approached Belgian graphics group Agfa-Gevaert about a possible takeover, the two companies said on Friday.
Agfa makes medical IT products, which would add to CompuGroup’s range of software for doctors’ offices, pharmacies and hospitals, and also has a portfolio of other products including X-ray machines.
The combined company would have annual sales of more than 3 billion euros ($3.3 billion).
CompuGroup said it had given Agfa’s board of directors a non-binding indication of interest but said it was not certain that it would end up making a firm offer.
“The discussions between the companies are at an early stage. No response has been given to the indication of interest and CompuGroup Medical SE has not been able to verify or discuss any of the assumptions and conditions underlying its indication of interest,” CompuGroup said.
Agfa, whose market value has shrunk by a third to 616 million euros this year, said its board would evaluate CompuGroup’s approach carefully.
The news sent shares in Agfa up 6.2 percent to a six-month high of 3.80 euros.
CompuGroup shares were down 3.7 percent in early trade, with traders citing concerns that the German company would be overtaxing itself with a takeover of Agfa.
“We think a takeover offer by CompuGroup will only occur if they have a solution for Agfa Graphics and the 1.25 billion euros pension liabilities in hand,” analysts at KBC said in a note to clients.
CompuGroup has grown through a series of bolt-on acquisitions in recent years, most recently buying a majority in Vega, an Italian distributor of its software, last month.
Agfa, which in 2004 sold its eponymous camera film business which made it a household name, is active in the printing and medical imaging business.
Its healthcare business accounts for about 40 percent of its 2.6 billion euros in annual revenue. ($1 = 0.9158 euros)
By Maria Sheahan and Robert-Jan Bartunek
Source: Reuters
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
